title: Neutrophil-lymphocyte ratio in Crohn's disease patients predicts sustained response to infliximab 52-week therapy.
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Lodz, Poland. dr.mwlodarczyk@gmail.com.
authors.forename: Marcin K
authors.initials: MK
authors.lastname: Wlodarczyk
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Lodz, Poland.
authors.forename: Aleksandra E
authors.initials: AE
authors.lastname: Sobolewska
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Lodz, Poland.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Stec-Michalska
authors.affiliation: Department of Biochemistry, Medical University of Lodz, Lodz, Poland.
authors.forename: Jakub J
authors.initials: JJ
authors.lastname: Fichna
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Lodz, Poland.
authors.forename: Maria E
authors.initials: ME
authors.lastname: Wisniewska-Jarosinska
mesh_terms: D003424:Crohn Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000069285:Infliximab